Summary
19.17 -0.01(-0.03%)07/02/2024
Fresenius Medical Care AG & Co. KGaA (FMS)
Fresenius Medical Care AG & Co. KGaA (FMS)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.03 | -0.39 | -9.79 | 2.10 | -9.81 | -19.31 | -47.22 | 168.74 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 19.17 | |
| Open | 19.02 | |
| High | 19.20 | |
| Low | 18.98 | |
| Volume | 156,112 | |
| Change | -0.01 | |
| Change % | -0.03 | |
| Avg Volume (20 Days) | 390,471 | |
| Volume/Avg Volume (20 Days) Ratio | 0.40 | |
| 52 Week Range | 16.37 - 27.72 | |
| Price vs 52 Week High | -30.86% | |
| Price vs 52 Week Low | 17.07% | |
| Range | 0.76 | |
| Gap Up/Down | -0.35 | |
Fundamentals | ||
| Market Capitalization (Mln) | 11,244 | |
| EBIDTA | 2,508,497,920 | |
| PE Ratio | 24.4045 | |
| PEG Ratio | 0.3923 | |
| WallStreet Target Price | 18.95 | |
| Book Value | 47.3980 | |
| Earnings Per Share | 0.8900 | |
| EPS Estimate Current Quarter | 0.2600 | |
| EPS Estimate Next Quarter | 0.3700 | |
| EPS Estimate Current Year | 2.0400 | |
| EPS Estimate Next Year | 2.5600 | |
| Diluted EPS (TTM) | 0.8900 | |
| Revenues | ||
| Profit Marging | 0.0248 | |
| Operating Marging (TTM) | 0.0765 | |
| Return on asset (TTM) | 0.0283 | |
| Return on equity (TTM) | 0.0472 | |
| Revenue TTM | 19,473,920,000 | |
| Revenue per share TTM | 33.1850 | |
| Quarterly Revenue Growth (YOY) | 0.0040 | |
| Quarterly Earnings Growth (YOY) | -0.1720 | |
| Gross Profit (TTM) | 5,310,252,000 | |
| Dividends | ||
| Dividend Share | 1.1900 | |
| Dividend Yield | 0.0292 | |
| Valuations | ||
| Trailing PE | 24.4045 | |
| Forward PE | 10.5152 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.7377 | |
| Revenue Enterprise Value | 1.1343 | |
| EBITDA Enterprise Value | 6.8749 | |
| Shares | ||
| Shares Outstanding | 586,827,008 | |
| Shares Float | 198,937,253 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.00 | |
| Institutions (%) | 7.33 | |
07/01 07:10 EST - globenewswire.com
Bridger Aerospace Acquires FMS Aerospace, Boosting In-House Engineering Capabilities and Diversifying its Customer Base and Seasonality
BELGRADE, Mont., July 01, 2024 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation's largest aerial firefighting companies, today announced that it has acquired FMS Aerospace (“FMS”). FMS, based in Huntsville, Alabama, is a turn-key provider of airframe modification and integration solutions for government and commercial customers including instrumentation, flight testing and airworthiness certification. The consideration for the transaction was $17.51 million in equity, with an additional contingent equity earn-out consideration of up to $3.09 million.
Bridger Aerospace Acquires FMS Aerospace, Boosting In-House Engineering Capabilities and Diversifying its Customer Base and Seasonality
BELGRADE, Mont., July 01, 2024 (GLOBE NEWSWIRE) -- Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation's largest aerial firefighting companies, today announced that it has acquired FMS Aerospace (“FMS”). FMS, based in Huntsville, Alabama, is a turn-key provider of airframe modification and integration solutions for government and commercial customers including instrumentation, flight testing and airworthiness certification. The consideration for the transaction was $17.51 million in equity, with an additional contingent equity earn-out consideration of up to $3.09 million.
06/19 10:45 EST - zacks.com
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Fresenius (FMS) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
06/12 08:00 EST - prnewswire.com
Fresenius Medical Care takes next important step towards goal to reduce CO2 emissions in its operations
Fresenius Medical Care enters virtual power purchase agreements for renewable energy to clearly step forward in reducing CO2 emissions footprint Company enacts five virtual power purchase agreements for around 580 gigawatt hours per year with wind and solar farms in Germany and the U.S. Energy farms scheduled to go into operation in 2024 and 2025 Important milestone for strategic sustainability goal to achieve climate-neutrality by 2040 BAD HOMBURG, Germany , June 12, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, has signed five virtual power purchase agreements (vPPAs) with wind and solar energy project developers in Germany and the U.S. The projects are expected to feed around 580 gigawatt hours of renewable energy into the grid, which equals up to 46 percent of FME's most recently reported global consumption. The company is thus taking an important step towards its goal of reducing emissions in its own operations (Scope 1 and 2) by 50 percent by 2030.
Fresenius Medical Care takes next important step towards goal to reduce CO2 emissions in its operations
Fresenius Medical Care enters virtual power purchase agreements for renewable energy to clearly step forward in reducing CO2 emissions footprint Company enacts five virtual power purchase agreements for around 580 gigawatt hours per year with wind and solar farms in Germany and the U.S. Energy farms scheduled to go into operation in 2024 and 2025 Important milestone for strategic sustainability goal to achieve climate-neutrality by 2040 BAD HOMBURG, Germany , June 12, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, has signed five virtual power purchase agreements (vPPAs) with wind and solar energy project developers in Germany and the U.S. The projects are expected to feed around 580 gigawatt hours of renewable energy into the grid, which equals up to 46 percent of FME's most recently reported global consumption. The company is thus taking an important step towards its goal of reducing emissions in its own operations (Scope 1 and 2) by 50 percent by 2030.
06/07 12:06 EST - zacks.com
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
05/24 09:27 EST - marketwatch.com
Ozempic cuts kidney-disease risks, research finds
Novo Nordisk's diabetes drug Ozempic reduces the risk of kidney failure and death in patients who have both Type 2 diabetes and chronic kidney disease, according to new research published Friday in the New England Journal of Medicine.
Ozempic cuts kidney-disease risks, research finds
Novo Nordisk's diabetes drug Ozempic reduces the risk of kidney failure and death in patients who have both Type 2 diabetes and chronic kidney disease, according to new research published Friday in the New England Journal of Medicine.
05/23 12:33 EST - prnewswire.com
Moody's and S&P change Fresenius Medical Care's rating outlook to stable
The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress Solid deleveraging prospects BAD HOMBURG, Germany , May 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today received from S&P Global, a leading rating agency, the change of its rating outlook to stable from negative (bbb-, stable outlook). Moody's changed the credit rating outlook from negative to stable on May 17 (baa3, stable outlook).
Moody's and S&P change Fresenius Medical Care's rating outlook to stable
The change of the rating outlook reflects the company's progress in restoring credit metrics and the commitment to maintain its investment grade rating FME is expected to maintain its good growth momentum, while continuing to improve operational performance on the back of its strong transformation progress Solid deleveraging prospects BAD HOMBURG, Germany , May 23, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today received from S&P Global, a leading rating agency, the change of its rating outlook to stable from negative (bbb-, stable outlook). Moody's changed the credit rating outlook from negative to stable on May 17 (baa3, stable outlook).
05/21 10:00 EST - prnewswire.com
Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024
Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence Company-wide experts highlight robust anonymized dialysis database CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented BAD HOMBURG, Germany , May 21, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of nearly 40 company-affiliated research abstracts at the 61st European Renal Association (ERA) Congress, taking place May 23-26, 2024, in Stockholm, Sweden and virtually. "Our mission to improve the lives of people living with kidney disease requires working continually to enhance the standard of kidney disease care, and research plays an important role in that advancement," said Dr. Frank Maddux, Global Chief Medical Officer and Member of the Management Board for Fresenius Medical Care.
Fresenius Medical Care showcases leadership and innovation in kidney care disease at 61st European Renal Association (ERA) Congress 2024
Enhancing kidney care through innovative approaches by data-driven insights and real-world evidence Company-wide experts highlight robust anonymized dialysis database CONVINCE study and the remarkable decrease of 23% in mortality rates for patients treated with high-volume hemodiafiltration will be presented BAD HOMBURG, Germany , May 21, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of nearly 40 company-affiliated research abstracts at the 61st European Renal Association (ERA) Congress, taking place May 23-26, 2024, in Stockholm, Sweden and virtually. "Our mission to improve the lives of people living with kidney disease requires working continually to enhance the standard of kidney disease care, and research plays an important role in that advancement," said Dr. Frank Maddux, Global Chief Medical Officer and Member of the Management Board for Fresenius Medical Care.
05/20 01:18 EST - https://www.defenseworld.net
Analyzing Ryder System (NYSE:R) and Zoomcar (NASDAQ:ZCAR)
Ryder System (NYSE:R – Get Free Report) and Zoomcar (NASDAQ:ZCAR – Get Free Report) are both transportation companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings. Profitability This table compares Ryder System and Zoomcar’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Ryder System 2.95% 18.38% 3.62% Zoomcar N/A -13.53% 48.39% Analyst Recommendations This is a breakdown of current ratings and recommmendations for Ryder System and Zoomcar, as reported by MarketBeat. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ryder System 0 5 2 0 2.29 Zoomcar 0 0 0 0 N/A Ryder System presently has a consensus target price of $126.83, indicating a potential upside of 0.88%. Given Ryder System’s higher possible upside, analysts plainly believe Ryder System is more favorable than Zoomcar. Institutional & Insider Ownership 87.5% of Ryder System shares are owned by institutional investors. Comparatively, 3.7% of Zoomcar shares are owned by institutional investors. 5.1% of Ryder System shares are owned by insiders. Comparatively, 2.2% of Zoomcar shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Risk and Volatility Ryder System has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Zoomcar has a beta of -0.31, suggesting that its share price is 131% less volatile than the S&P 500. Earnings & Valuation This table compares Ryder System and Zoomcar’s revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ryder System $12.07 billion 0.46 $406.00 million $7.68 16.37 Zoomcar $9.87 million 1.56 -$4.63 million N/A N/A Ryder System has higher revenue and earnings than Zoomcar. Summary Ryder System beats Zoomcar on 9 of the 11 factors compared between the two stocks. About Ryder System (Get Free Report) Ryder System, Inc. operates as a logistics and transportation company worldwide. It operates through three segments: Fleet Management Solutions (FMS), Supply Chain Solutions (SCS), and Dedicated Transportation Solutions (DTS). The FMS segment offers full-service leasing and leasing with flexible maintenance options; commercial vehicle rental services; and contract or transactional maintenance services of trucks, tractors, and trailers; access to diesel fuel; and fuel planning and tax reporting, cards, and monitoring services, and centralized billing, as well as sells used vehicles through its retail sales centers and www.ryder.com/used-trucks website, as well as digital and technology support services. The DTS segment offers equipment, maintenance, drivers, administrative, and additional services, as well as routing and scheduling, fleet sizing, safety, regulatory compliance, risk management, and technology and communication systems support services. The SCS segment comprises distribution management services, such as designing and managing customer's distribution network and facilities; coordinating warehousing and transportation for inbound and outbound material flows; handling import and export for international shipments; coordinating just-in-time replenishment of component parts to manufacturing and final assembly; and offering shipments to customer distribution centers or end customer delivery points, as well as other value added services, such as light assembly of components. This segment also offers transportation management and brokerage services, such as shipment optimization, load scheduling, and delivery confirmation services; knowledge-based professional services; and e-commerce and last mile services. The company was founded in 1933 and is headquartered in Coral Gables, Florida. About Zoomcar (Get Free Report) Zoomcar Holdings, Inc. operates a marketplace for car sharing in India, Indonesia, and Egypt. It connects hosts with guests, who choose from a selection of cars for use at affordable prices, promoting smart transportation solutions. The company was founded in 2013 and is based in Bronxville, New York.
Analyzing Ryder System (NYSE:R) and Zoomcar (NASDAQ:ZCAR)
Ryder System (NYSE:R – Get Free Report) and Zoomcar (NASDAQ:ZCAR – Get Free Report) are both transportation companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings. Profitability This table compares Ryder System and Zoomcar’s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Ryder System 2.95% 18.38% 3.62% Zoomcar N/A -13.53% 48.39% Analyst Recommendations This is a breakdown of current ratings and recommmendations for Ryder System and Zoomcar, as reported by MarketBeat. Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ryder System 0 5 2 0 2.29 Zoomcar 0 0 0 0 N/A Ryder System presently has a consensus target price of $126.83, indicating a potential upside of 0.88%. Given Ryder System’s higher possible upside, analysts plainly believe Ryder System is more favorable than Zoomcar. Institutional & Insider Ownership 87.5% of Ryder System shares are owned by institutional investors. Comparatively, 3.7% of Zoomcar shares are owned by institutional investors. 5.1% of Ryder System shares are owned by insiders. Comparatively, 2.2% of Zoomcar shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Risk and Volatility Ryder System has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, Zoomcar has a beta of -0.31, suggesting that its share price is 131% less volatile than the S&P 500. Earnings & Valuation This table compares Ryder System and Zoomcar’s revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ryder System $12.07 billion 0.46 $406.00 million $7.68 16.37 Zoomcar $9.87 million 1.56 -$4.63 million N/A N/A Ryder System has higher revenue and earnings than Zoomcar. Summary Ryder System beats Zoomcar on 9 of the 11 factors compared between the two stocks. About Ryder System (Get Free Report) Ryder System, Inc. operates as a logistics and transportation company worldwide. It operates through three segments: Fleet Management Solutions (FMS), Supply Chain Solutions (SCS), and Dedicated Transportation Solutions (DTS). The FMS segment offers full-service leasing and leasing with flexible maintenance options; commercial vehicle rental services; and contract or transactional maintenance services of trucks, tractors, and trailers; access to diesel fuel; and fuel planning and tax reporting, cards, and monitoring services, and centralized billing, as well as sells used vehicles through its retail sales centers and www.ryder.com/used-trucks website, as well as digital and technology support services. The DTS segment offers equipment, maintenance, drivers, administrative, and additional services, as well as routing and scheduling, fleet sizing, safety, regulatory compliance, risk management, and technology and communication systems support services. The SCS segment comprises distribution management services, such as designing and managing customer's distribution network and facilities; coordinating warehousing and transportation for inbound and outbound material flows; handling import and export for international shipments; coordinating just-in-time replenishment of component parts to manufacturing and final assembly; and offering shipments to customer distribution centers or end customer delivery points, as well as other value added services, such as light assembly of components. This segment also offers transportation management and brokerage services, such as shipment optimization, load scheduling, and delivery confirmation services; knowledge-based professional services; and e-commerce and last mile services. The company was founded in 1933 and is headquartered in Coral Gables, Florida. About Zoomcar (Get Free Report) Zoomcar Holdings, Inc. operates a marketplace for car sharing in India, Indonesia, and Egypt. It connects hosts with guests, who choose from a selection of cars for use at affordable prices, promoting smart transportation solutions. The company was founded in 2013 and is based in Bronxville, New York.
05/16 09:55 EST - prnewswire.com
Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets
Today's Annual General Meeting was the first one following the change in legal form completed in November 2023 Shareholders voted in favor of the proposed dividend of 1.19 euros, representing an increase of around 6 percent compared to the previous year New compensation system for Management Board approved Ambitious growth targets for 2024 confirmed BAD HOMBURG, Germany , May 16, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the global leader in providing products and services for people with kidney diseases, is executing its strategic turnaround plan and is well on track to achieve its goals for 2024. At today's Annual General Meeting, Michael Sen , Chairman of the Supervisory Board of Fresenius Medical Care AG, said: "Fresenius Medical Care has made significant progress in 2023.
Fresenius Medical Care Annual General Meeting: Company makes significant progress in its Transformation Efforts and confirms its ambitious 2024 Growth Targets
Today's Annual General Meeting was the first one following the change in legal form completed in November 2023 Shareholders voted in favor of the proposed dividend of 1.19 euros, representing an increase of around 6 percent compared to the previous year New compensation system for Management Board approved Ambitious growth targets for 2024 confirmed BAD HOMBURG, Germany , May 16, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the global leader in providing products and services for people with kidney diseases, is executing its strategic turnaround plan and is well on track to achieve its goals for 2024. At today's Annual General Meeting, Michael Sen , Chairman of the Supervisory Board of Fresenius Medical Care AG, said: "Fresenius Medical Care has made significant progress in 2023.
05/11 06:42 EST - reuters.com
Fresenius Medical sees up to 2% US dialysis growth by year-end
The number of kidney dialysis sessions provided by Fresenius Medical Care in its top market, the United States, could rise by as much as 2% by the end of the year, its CEO said, as the impact of the pandemic on patients fades.
Fresenius Medical sees up to 2% US dialysis growth by year-end
The number of kidney dialysis sessions provided by Fresenius Medical Care in its top market, the United States, could rise by as much as 2% by the end of the year, its CEO said, as the impact of the pandemic on patients fades.
05/08 12:26 EST - zacks.com
Fresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up
Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
Fresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up
Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.
05/07 14:53 EST - seekingalpha.com
Fresenius Medical Care AG (FMS) Q1 2024 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS ) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Dominik Heger - Head, IR Helen Giza - CEO and Chair Martin Fischer - CFO Conference Call Participants Richard Felton - Goldman Sachs Victoria Lambert - Berenberg James Vane-Tempest - Jefferies Veronika Dubajova - Citi Graham Doyle - UBS Lisa Clive - Bernstein Robert Davies - Morgan Stanley Hugo Solvet - Exane BNP Paribas Oliver Metzger - ODDO BHF Falko Friedrichs - Deutsche Bank Dominik Heger Thank you, Alice. Good afternoon or good morning, depending on where you are.
Fresenius Medical Care AG (FMS) Q1 2024 Earnings Call Transcript
Fresenius Medical Care AG (NYSE:FMS ) Q1 2024 Earnings Conference Call May 7, 2024 8:00 AM ET Company Participants Dominik Heger - Head, IR Helen Giza - CEO and Chair Martin Fischer - CFO Conference Call Participants Richard Felton - Goldman Sachs Victoria Lambert - Berenberg James Vane-Tempest - Jefferies Veronika Dubajova - Citi Graham Doyle - UBS Lisa Clive - Bernstein Robert Davies - Morgan Stanley Hugo Solvet - Exane BNP Paribas Oliver Metzger - ODDO BHF Falko Friedrichs - Deutsche Bank Dominik Heger Thank you, Alice. Good afternoon or good morning, depending on where you are.
05/07 10:30 EST - youtube.com
We have positive momentum in operating performance: Fresenius Medical Care CEO
Helen Giza, CEO of Fresenius Medical Care, joins CNBC's Annette Weisbach to discuss the company's 2024 first-quarter earnings results.
We have positive momentum in operating performance: Fresenius Medical Care CEO
Helen Giza, CEO of Fresenius Medical Care, joins CNBC's Annette Weisbach to discuss the company's 2024 first-quarter earnings results.
05/07 07:00 EST - prnewswire.com
Fresenius Medical Care starts the year with strong earnings growth
Solid revenue1 growth of 4% driven by both segments Care Delivery and Care Enablement Operating income1 margin improved in both segments Care Enablement delivered strong sequential margin improvement with significant progress towards the 2025 target margin band Execution of transformation continues at pace, contributing additional FME25 savings of EUR 52 million Portfolio optimization program progresses in Care Delivery with signed or closed divestments in all our Latin American markets, and closed divestments in Turkiye and of Cura Day Hospitals Group in Australia FY 2024 outlook confirmed BAD HOMBURG, Germany , May 7, 2024 /PRNewswire/ -- Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "The first quarter of this year demonstrates that we are executing on our strategy as planned. Both segments expanded their respective margins compared to the prior year.
Fresenius Medical Care starts the year with strong earnings growth
Solid revenue1 growth of 4% driven by both segments Care Delivery and Care Enablement Operating income1 margin improved in both segments Care Enablement delivered strong sequential margin improvement with significant progress towards the 2025 target margin band Execution of transformation continues at pace, contributing additional FME25 savings of EUR 52 million Portfolio optimization program progresses in Care Delivery with signed or closed divestments in all our Latin American markets, and closed divestments in Turkiye and of Cura Day Hospitals Group in Australia FY 2024 outlook confirmed BAD HOMBURG, Germany , May 7, 2024 /PRNewswire/ -- Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "The first quarter of this year demonstrates that we are executing on our strategy as planned. Both segments expanded their respective margins compared to the prior year.
05/07 04:08 EST - reuters.com
Fresenius Medical beats earnings expectations, keeps outlook; shares sink
Fresenius Medical Care beat first-quarter operating earnings expectations on Tuesday amid higher pricing and cost-cut savings, but the German company still maintained its profit outlook for 2024, sending its shares down in early trading.
Fresenius Medical beats earnings expectations, keeps outlook; shares sink
Fresenius Medical Care beat first-quarter operating earnings expectations on Tuesday amid higher pricing and cost-cut savings, but the German company still maintained its profit outlook for 2024, sending its shares down in early trading.
04/11 10:36 EST - zacks.com
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.
3 Medical Device Stocks With Solid Dividend Yield: CAH & Others
Here we discuss three medical device stocks, Cardinal Health (CAH), Baxter International (BAX) and Fresenius Medical Care (FMS), with a solid five-year dividend growth history.
03/25 12:11 EST - zacks.com
Fresenius Medical (FMS) to Unveil Training on Augmented Reality
Fresenius Medical (FMS) is launching digital learning elements with hands-on training for Kidney Replacement Therapy leveraging Augmented Reality.
Fresenius Medical (FMS) to Unveil Training on Augmented Reality
Fresenius Medical (FMS) is launching digital learning elements with hands-on training for Kidney Replacement Therapy leveraging Augmented Reality.
03/22 08:00 EST - prnewswire.com
Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care
Fresenius Medical Care delivers on commitments during a year of fundamental transformation Progress towards sustainability goals in key areas: patient satisfaction, diversity in management, climate target roadmap BAD HOMBURG, Germany , March 22, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today published its joint 2023 Annual Report and Non-financial Group Report, available digitally on the corporate website. Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.
Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care
Fresenius Medical Care delivers on commitments during a year of fundamental transformation Progress towards sustainability goals in key areas: patient satisfaction, diversity in management, climate target roadmap BAD HOMBURG, Germany , March 22, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today published its joint 2023 Annual Report and Non-financial Group Report, available digitally on the corporate website. Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.
03/19 08:00 EST - prnewswire.com
Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device
For the first time, Fresenius Medical Care develops and utilizes "Augmented Reality" (AR) to train medical staff in Intensive Care Units (ICUs) The new training application for ICU staff combines digital learning elements with real-life training on the Fresenius Medical Care Continuous Kidney Replacement Therapy system This learning experience reinforces initial training, a supplement to support new staff amidst the high fluctuation of specialists in intensive care nursing BAD HOMBURG, Germany , March 19, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, launches a new "Augmented Reality" (AR) application to make learning easier for nursing staff in Kidney Replacement Therapy in Intensive Care Units. The AR glasses, in combination with digital learning modules, allow nursing staff to learn how to use acute dialysis machines on site within the intensive care wards.
Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device
For the first time, Fresenius Medical Care develops and utilizes "Augmented Reality" (AR) to train medical staff in Intensive Care Units (ICUs) The new training application for ICU staff combines digital learning elements with real-life training on the Fresenius Medical Care Continuous Kidney Replacement Therapy system This learning experience reinforces initial training, a supplement to support new staff amidst the high fluctuation of specialists in intensive care nursing BAD HOMBURG, Germany , March 19, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, launches a new "Augmented Reality" (AR) application to make learning easier for nursing staff in Kidney Replacement Therapy in Intensive Care Units. The AR glasses, in combination with digital learning modules, allow nursing staff to learn how to use acute dialysis machines on site within the intensive care wards.